Business context and reporting period
Entity mismatch: The request identifies Tempest Therapeutics, Inc., but the supplied filing is Millendo Therapeutics, Inc.’s Form 10-K. This summary covers Millendo’s fiscal year ended December 31, 2019, not a standalone 2019 fourth quarter. The company was a clinical-stage biopharmaceutical business developing treatments for endocrine diseases; it had no approved products and no product-sales revenue.
Financial performance and position
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $27.8 million | $14.4 million |
| General and administrative expense | $17.6 million | $8.7 million |
| Operating loss | $45.4 million | $26.9 million |
| Net loss | $44.6 million | $27.2 million |
| Net loss per share, basic and diluted | $3.25 | $17.58 |
| Net cash used in operating activities | $41.2 million | $23.6 million |
Gross profit and operating margins are not meaningful because the company reported no product-sales revenue. At year-end, cash and cash equivalents were $62.5 million, restricted cash $1.0 million, and marketable securities nil; total cash, cash equivalents, and restricted cash were $63.5 million. Total assets were $75.0 million, total liabilities $15.1 million, and stockholders’ equity $59.9 million. Debt totaled approximately $0.4 million, due through 2021, with no interest charged on the Bpifrance advance. Operating lease liabilities were $4.1 million.
Financing provided $26.9 million net cash in 2019, principally from a December stock offering that raised approximately $26.5 million net. The company reported an accumulated deficit of $208.7 million. Management said year-end liquidity, together with approximately $5.5 million in estimated net ATM proceeds raised in March 2020, was expected to fund current operating plans into 2022; this estimate depended on existing plans and excluded potential changes or additional activities.
Material changes versus the prior comparable period
- Net loss increased by $17.4 million; operating cash use increased by $17.6 million.
- R&D expense rose $13.4 million, mainly as livoletide development advanced. G&A expense rose $8.9 million, reflecting higher compensation, public-company professional fees, insurance, and facilities costs.
- 2018 included $3.8 million of merger-related expenses; none were reported in 2019.
- Common shares outstanding increased to 18.3 million at December 31, 2019 from 13.4 million a year earlier, largely reflecting the December 2019 offering.
Outlook, risks, contingencies, and unusual items
- Livoletide for Prader-Willi syndrome: The pivotal Phase 2b core period had been completed by February 26, 2020; 156 of 158 randomized participants completed it. Topline results were expected in early Q2 2020. The FDA granted Fast Track designation in July 2019. Earlier Phase 2a evidence included a statistically significant result in a prespecified subgroup, but the overall trial comparison was not statistically significant.
- Nevanimibe for congenital adrenal hyperplasia: Phase 2b was ongoing. First-cohort topline results and an update on second-cohort enrollment were expected in the second half of 2020. The prior Phase 2a trial enrolled only 10 patients and was not designed for formal statistical analysis.
- MLE-301: The NK3R antagonist was in preclinical development; first-in-human studies were expected in the second half of 2020.
- Program discontinuation: Millendo discontinued its Phase 2 Cushing’s syndrome trial and suspended nevanimibe development for that indication in August 2019 because enrollment was slower than anticipated.
- Key risks: Continued operating losses and need for future financing; uncertain trial outcomes, enrollment, regulatory approval, commercialization, and reimbursement; dependence on contract manufacturers and research organizations; competition; and potential dilution from equity financing. The filing also describes legacy OvaScience litigation. Potential losses were not estimable; the company said an adverse resolution of one securities class action could materially affect financial position and results.
- Other disclosures: The independent auditor issued an unqualified opinion on the financial statements and internal controls. Management reported effective disclosure controls and internal control over financial reporting as of year-end.
Most important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Millendo Therapeutics, not Tempest Therapeutics.
- Check the actual livoletide Phase 2b results and whether the planned Phase 3 study proceeded; the filing’s expected timing was forward-looking.
- Review subsequent nevanimibe and MLE-301 clinical progress, spending, and any changes to trial plans.
- Reassess cash runway against operating cash burn, financing proceeds, dilution, and any updated spending or partnering plans.
- Track outcomes of the legacy OvaScience lawsuits and any developments affecting potential liabilities.